Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.

http://www.alexion.com


ALXN $130.21 -4.00 (-2.98%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 29.72 Billion
EPS -0.20 P/E Ratio 372.03
Previous Earnings Wed, Oct 24, 2018
Latest Earnings Mon, Feb 4, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

130.21 29.72 372.03 0.00 ALXN NASDAQ -2.98 32.80 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALXN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALXN&exchange=NASDAQ&chart=1

Symbol Surfing has been referenced on Barrons, CNN & Investor Place.

About | Blog | Advertising | Terms | info@symbolsurfing.com

Investing Quotes #Legendary


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.

©2019 Symbol Surfing All Rights Reserved. Privacy Policy | ^Top